Amicus Therapeutics Stock News

Alliancebernstein L.P. increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 66.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 531,503 shares of the

Payment gateway Visa has further divided into crypto by joining hands with Fold to offer a new co-branded card with spent rewards in Bitcoin.

Bitcoin rewards for dollars spent. That's the allure of a new Visa credit card from e-commerce startup Fold.

Franklin Resources Inc. decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 49.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has received an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the

Nuveen Asset Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 92.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of some unusual options trading activity on Monday. Investors acquired 703 call options on the company. This is an increase of approximately 813%

If you own shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) then it's worth thinking about how it contributes to the...

Profund Advisors LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 24,809 shares of the

Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 15,003 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $9.

Bank of New York Mellon Corp lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,255,08

AQR Capital Management LLC decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 12.5% during the 4th quarter, according to its most recent 13F filing with the Securities and

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 9,755 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $9.08, for a total val

The healthcare sector is on the front lines of treating, preventing, and ultimately solving the coronavirus issues. We discuss with our panelists how the sector

Information on stock, financials, earnings, subsidiaries, investors, and executives for Amicus Therapeutics. Use the PitchBook Platform to explore the full profile.